Valvular & structural heart disease
Market Competition and Use of Transcatheter Aortic Valve Replacement in the United States
Main finding · Receipt of TAVRResult — go to the resultAdjusted odds ratio 1.68 CI 1.26–2.23Authors' conclusion
Increasing hospital market competition was linked with increased likelihood of TAVR, particularly among younger populations.
Study context
- Population
- Adults undergoing transcatheter aortic valve replacement (TAVR) or SAVR for aortic stenosis (AS), 2018–2021
- Participants
- 137,734 adults
- Exposure
- High vs low hospital market competition
- Competitiven = 83,650
- Outcome
- Receipt of TAVR
Methodological detailsrisk-adjusted, 7 HCUP State Inpatient Databases
- Risk-adjusted
- 7 HCUP State Inpatient Databases
Main finding
As reported in the abstract
Adjusted odds ratio
1.68
CI 1.26–2.23
Competitivevs Noncompetitive
adjusted OR 1.68 (CI 1.26–2.23)
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted OR (CI) | |
|---|---|---|
| Receipt of TAVR, by age (subgroup)Competitivevs NoncompetitiveAge <50 years | 1.54 (1.12–2.11) | |
| Receipt of TAVR, by age (subgroup)Competitivevs NoncompetitiveAge 50 to 60 years | 1.30 (1.14–1.48) | |
| 0.512Adjusted odds ratio (log scale) |
Per-patient costs
- Significantly greater per-patient costs with high market competition
Mortality and composite complications
- Similar odds of mortality and composite complications
Original publication
Market Competition and Use of Transcatheter Aortic Valve Replacement in the United States. JACC Adv. Published 15 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →